These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 34188916)

  • 1. Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy.
    Afolabi LO; Afolabi MO; Sani MM; Okunowo WO; Yan D; Chen L; Zhang Y; Wan X
    Clin Transl Immunology; 2021; 10(6):e1286. PubMed ID: 34188916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
    Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
    Ren J; Zhao Y
    Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9.
    Afolabi LO; Adeshakin AO; Sani MM; Bi J; Wan X
    Immunology; 2019 Oct; 158(2):63-69. PubMed ID: 31315144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
    Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
    Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
    Razeghian E; Nasution MKM; Rahman HS; Gardanova ZR; Abdelbasset WK; Aravindhan S; Bokov DO; Suksatan W; Nakhaei P; Shariatzadeh S; Marofi F; Yazdanifar M; Shamlou S; Motavalli R; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):428. PubMed ID: 34321099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems.
    Wang L; Chen Y; Liu X; Li Z; Dai X
    Front Oncol; 2021; 11():704999. PubMed ID: 35111663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges.
    Zhi L; Su X; Yin M; Zhang Z; Lu H; Niu Z; Guo C; Zhu W; Zhang X
    Cell Immunol; 2021 Nov; 369():104436. PubMed ID: 34500148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system.
    Hajifathali A; Lasemi MV; Mehravar M; Moshari MR; Alizadeh AM; Roshandel E
    Hematol Transfus Cell Ther; 2024; 46(1):58-66. PubMed ID: 37451978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy.
    Liu Z; Shi M; Ren Y; Xu H; Weng S; Ning W; Ge X; Liu L; Guo C; Duo M; Li L; Li J; Han X
    Mol Cancer; 2023 Feb; 22(1):35. PubMed ID: 36797756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy.
    Elmas E; Saljoughian N; de Souza Fernandes Pereira M; Tullius BP; Sorathia K; Nakkula RJ; Lee DA; Naeimi Kararoudi M
    Front Oncol; 2022; 12():834002. PubMed ID: 35449580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
    Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
    J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More.
    Ou X; Ma Q; Yin W; Ma X; He Z
    Front Cell Dev Biol; 2021; 9():674467. PubMed ID: 34095145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancements in CRISPR screens for the development of cancer immunotherapy strategies.
    Li YR; Lyu Z; Tian Y; Fang Y; Zhu Y; Chen Y; Yang L
    Mol Ther Oncolytics; 2023 Dec; 31():100733. PubMed ID: 37876793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy.
    Chen C; Wang Z; Qin Y
    Exp Hematol Oncol; 2023 Nov; 12(1):95. PubMed ID: 37964355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
    Hu KJ; Yin ETS; Hu YX; Huang H
    Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR, CAR-T, and NK: Current applications and future perspectives.
    Khoshandam M; Soltaninejad H; Hamidieh AA; Hosseinkhani S
    Genes Dis; 2024 Jul; 11(4):101121. PubMed ID: 38545126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.